PMID- 28610824 OWN - NLM STAT- MEDLINE DCOM- 20181105 LR - 20181105 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 36 IP - 36 DP - 2018 Aug 28 TI - Safety and perception: What are the greatest enemies of HPV vaccination programmes? PG - 5424-5429 LID - S0264-410X(17)30730-2 [pii] LID - 10.1016/j.vaccine.2017.05.071 [doi] AB - Vaccines stimulate a person's immune system to produce an adequate reaction against a specific infectious agent; i.e. the person is protected from that disease without having to get it first. As vaccines are administrated to healthy subjects, they are held to the highest standards of safety. Regarding human papillomavirus (HPV) vaccines, at present three prophylactic vaccines are licensed (bivalent HPV 16/18, quadrivalent HPV 6/11/16/18 and the nonovalent HPV 6/11/16/18/31/33/45/52/58 vaccine). Pre- and post-licensure studies (i.e. not yet for nonovalent HPV vaccine) confirm that HPV vaccines are generally safe and well-tolerated, site injections symptoms are the most common adverse events (AEs) reported, and pain is the most frequently referred local symptom. Serious AEs are rare and not associated with severe sequelae, at least no vaccine-related deaths have occurred. Despite these scientific evidences, it is still difficult to explain to the population the importance of a good vaccination programme. There are many determinants for HPV vaccines hesitancy which represent a barrier that must be overcome in order to increase vaccine coverage, including psychological reactions, religious or cultural aspects, and fear of possible AEs (demyelinating diseases, Complex Regional Pain Syndrome - CRPS, or Postural Orthostatic Tachycardia Syndrome - POTS). A weak communication strategy which frequently suffers due to spread of unverified news by media and websites may lead to the failure of a vaccination programme. Such a situation happened in Japan (2013), due to which a great number of women remain vulnerable to HPV-related cancers. In order to resolve the issues around HPV vaccines acceptance, it is necessary to use good communication strategies. Multicomponent and dialogue-based interventions seem to be the most effective, especially if an adequate language is used, customized according to the vaccination programme target. CI - Copyright (c) 2017 Elsevier Ltd. All rights reserved. FAU - Bonanni, Paolo AU - Bonanni P AD - Department of Health Sciences, University of Florence, Viale Morgagni 48, 50134 Florence, Italy. Electronic address: paolo.bonanni@unifi.it. FAU - Zanella, Beatrice AU - Zanella B AD - Department of Health Sciences, University of Florence, Viale Morgagni 48, 50134 Florence, Italy. Electronic address: beatrice.zanella@unifi.it. FAU - Santomauro, Francesca AU - Santomauro F AD - Department of Health Sciences, University of Florence, Viale Morgagni 48, 50134 Florence, Italy. Electronic address: francesca.santomauro@unifi.it. FAU - Lorini, Chiara AU - Lorini C AD - Department of Health Sciences, University of Florence, Viale Morgagni 48, 50134 Florence, Italy. Electronic address: chiara.lorini@unifi.it. FAU - Bechini, Angela AU - Bechini A AD - Department of Health Sciences, University of Florence, Viale Morgagni 48, 50134 Florence, Italy. Electronic address: angela.bechini@unifi.it. FAU - Boccalini, Sara AU - Boccalini S AD - Department of Health Sciences, University of Florence, Viale Morgagni 48, 50134 Florence, Italy. Electronic address: sara.boccalini@unifi.it. LA - eng PT - Journal Article DEP - 20170610 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Papillomavirus Vaccines) SB - IM MH - Demyelinating Diseases/immunology/prevention & control MH - Human papillomavirus 16/immunology/*pathogenicity MH - Human papillomavirus 18/immunology/*pathogenicity MH - Humans MH - Immunization Programs/methods MH - Papillomavirus Vaccines/adverse effects/*therapeutic use MH - Vaccination/adverse effects/*methods OTO - NOTNLM OT - Communication OT - HPV OT - Safety OT - Vaccine OT - Vaccine hesitancy EDAT- 2017/06/15 06:00 MHDA- 2018/11/06 06:00 CRDT- 2017/06/15 06:00 PHST- 2017/01/31 00:00 [received] PHST- 2017/05/05 00:00 [revised] PHST- 2017/05/24 00:00 [accepted] PHST- 2017/06/15 06:00 [pubmed] PHST- 2018/11/06 06:00 [medline] PHST- 2017/06/15 06:00 [entrez] AID - S0264-410X(17)30730-2 [pii] AID - 10.1016/j.vaccine.2017.05.071 [doi] PST - ppublish SO - Vaccine. 2018 Aug 28;36(36):5424-5429. doi: 10.1016/j.vaccine.2017.05.071. Epub 2017 Jun 10.